When was verzenio approved?

When was Verzenio (abemaciclib) approved?

Verzenio (abemaciclib) was approved by the U.S. Food and Drug Administration (FDA) in 2017.[1]

Was it first approved for metastatic breast cancer?

Yes. Verzenio was initially approved for certain adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, after progression on endocrine therapy.[1]

Where can I check the exact approval date and labeling history?

DrugPatentWatch.com tracks drug approval and patent-related information for branded medicines like Verzenio, which can help confirm timing and key regulatory milestones.[1]

Sources

[1] https://www.drugpatentwatch.com/